ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 428 • 2012 ACR/ARHP Annual Meeting

    TNFα Modulates the Expression of Circadian Clock Gene, Per2, Via D-Box Motif in the Promoter Region in Rheumatoid Synovial Cells

    Kohsuke Yoshida1, Akira Hashiramoto2, Takaichi Okano3, Nao Shibanuma4 and Shunichi Shiozawa5, 1Hyogo Prefectural Rehabilitation Center at Nishi-harima, Tatsuno, Japan, 2Department of Internal Medicine, Kobe University Graduate School of Medicine / The Center for Rheumatic Diseases, Kobe University Hospital, Kobe, Japan, 3The Center for Rheumatic Diseases,, Kobe University Hospital, Kobe, Japan, 4The Center for Rheumatic Diseases, Kobe University Hospital / Departmant of Orthopaedic Surgery, Kobe Kaisei Hospital, Kobe, Japan, 5Department of Medicine, Kyushu University Beppu Hospital, Beppu, Japan

    Background/Purpose: The mammalian clock genes including Clock (circadian locomotor output cycles kaput), Bmal1 (brain and muscle Arnt-like protein 1), Per (Period) and Cry (Cryptochrome) regulate…
  • Abstract Number: 429 • 2012 ACR/ARHP Annual Meeting

    The Significance of the Apoptosis Level and the Apoptosis Related Signal Proteins of CD4+t�ACD4+Foxp3+t Cell in Patients with Rheumatoid Arthritis

    Ning Li1, Tianrui Ma2, Jie Han1, Jieru Zhou1 and Songguo Zheng3, 1Rheumatology, Shanghai East Hospital, Shanghai, China, 2Rheumatology, Ningbo Pediatric Hospital, Ningbo, China, 3Division of Rheumatology and Immunology, Department of Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA

    Background/Purpose: To investigate the apoptosis of CD4+T cell and Tregs in the pathogenesis and disease activity of rheumatoid arthritis patients. Methods: Isolated lymphocytes from human…
  • Abstract Number: 390 • 2012 ACR/ARHP Annual Meeting

    Performance of Criteria for Remission in a Long-Term Observational Study of Patients with Early Rheumatoid Arthritis

    Bjorn Svensson1, Maria LE Andersson2, Sidona-Valentina Bala3, Kristina Forslind4 and Ingiäld Hafström5, 1Section of Rheumatology, Institution of Clinical Science, Lund University, Lund, Sweden, 2R&D Center, Spenshult Hospital, Oskarström, Sweden, 3Department of Health Sciences,, Lund University, Lund, Sweden, 4Department of Medicine, Karolinska Institute, Stockholm, Department of Medicine, Karolinska Institute,, Stockholm, Sweden, 5Unit of Rheumatology, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden

    Background/Purpose: Remission is widely accepted as the goal of treatment in RA and has to be sustained to keep joint damage at a minimum (Smolen…
  • Abstract Number: 391 • 2012 ACR/ARHP Annual Meeting

    DAS28 Is Not a Sufficient Disease Activity Measure for Obese Rheumatoid Arthritis Patients – Don’t Leave the Feet Behind

    Vikram Garg1, Paul Maranian2, Mihaela B. Taylor3, Harold E. Paulus4, David Elashoff5 and Veena K. Ranganath6, 1Division of Rheumatology, UCLA David Geffen School of Medicine, VA Greater Los Angeles Healthcare System, Los Angeles, CA, 2Division of Rheumatology, UCLA Medical School, Los Angeles, CA, 3Rheumatology, University of California Los Angeles, Los Angeles, CA, 4Medicine-Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, 5Departments of Biostatistics and Medicine, University of California, Los Angeles, Los Angeles, CA, 6Medicine/Rheumatology, University of California, Los Angeles, Western Consortium of Practicing Rheumatologists, Los Angeles, CA

    Background/Purpose: Current literature suggests that obesity impacts disease activity in rheumatoid arthritis (RA) and the incidence of obesity is on the rise. The objective of…
  • Abstract Number: 392 • 2012 ACR/ARHP Annual Meeting

    Analysis of Factors Impact On Patient Global Assessment in Daily Practice Based On Observational Cohort IORRA (Institute of Rheumatology, Rheumatoid Arthritis)

    Yasushi Inoue1, Eiichi Tanaka2, Ayako Nakajima3, Eisuke Inoue4, Akiko Kobayashi4, Daisuke Hoshi1, Naoki Sugimoto4, Kumi Shidara4, Yohei Seto4, Atsuo Taniguchi4, Shigeki Momohara1 and Hisashi Yamanaka1, 1Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 2Tokyo Women's Medical University, Tokyo, Japan, 3Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, 4Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan

    Background/Purpose: Patient global assessment (PtGA) is an element of the new ACR/EULAR remission criteria for rheumatoid arthritis (RA). This definition has been reported to better…
  • Abstract Number: 393 • 2012 ACR/ARHP Annual Meeting

    Defining Criteria for Rheumatoid Arthritis Patient-Derived Disease Activity Score That Corrresponds to Disease Activity Score 28 and Clnical Disease Activity Index Based Statuses and Response Criteria

    Alexander MH Leung1, Daniel Farewell2, Chak S. Lau3 and Ernest Choy4, 1Department of Rheumatology, Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom, 2Institute of Primary Care and Public Health, Cardiff, ENGLAND, United Kingdom, 3Univ Dept of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, 4Section of Rheumatology, Cardiff University School of Medicine, Cardiff, United Kingdom

    Background/Purpose: Patient-based disease activity score (PDAS1 [with ESR] & PDAS2 [without ESR]) in rheumatoid arthritis (RA) are validated patient reported outcome measures of disease activity.…
  • Abstract Number: 394 • 2012 ACR/ARHP Annual Meeting

    Remission After One Year in ACPA Positive and ACPA Negative Patients with Early Arthritis

    K.V.C. Wevers-de Boer1, L. Heimans1, K. Visser1, A.A. Schouffoer2, T.H.E. Molenaar3, J.B. Harbers4, C. Bijkerk5, I. Speyer6, M. de Buck7, P.B. de Sonnaville8, B.A. Grillet9, Tom Huizinga1 and C.F. Allaart1, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Rheumatology, Haga Hospital, The Hague, Netherlands, 3Dept of Rheumatology, Groene Hart Hospital, Gouda, Netherlands, 4Franciscus Hospital, Roosendaal, 5Rheumatology, Reinier de Graaf Gasthuis, Delft, Netherlands, 6Rheumatology, Bronovo Hospital, Den Haag, Netherlands, 7MCH, The Hague, 8Department of Rheumatology, Admiraal de Ruyter hospital, Goes, Netherlands, 9Department of Rheumatology, Zorgsaam Hospital, Terneuzen, Netherlands

    Background/Purpose: To evaluate possible differences in clinical response after one year of remission steered treatment in Anti Citrullinated Protein Antibody (ACPA) positive and negative RA…
  • Abstract Number: 395 • 2012 ACR/ARHP Annual Meeting

    Trends in Disease Activity, Response and Remission Rates in Rheumatoid Arthritis During the Last Decade: Results From the NOR-DMARD Register

    Anna-Birgitte Aga1, Elisabeth Lie2, Karen M. Fagerli2, Till Uhlig2, Tore K. Kvien2 and Espen A. Haavardsholm3, 1Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 2Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 3Diakonhjemmet Hospital, Oslo, Norway

    Background/Purpose: During the past decade there has been an increasing focus on early, aggressive treatment of patients with rheumatoid arthritis (RA), and combined with the…
  • Abstract Number: 396 • 2012 ACR/ARHP Annual Meeting

    Prevalence, Concordance and Predictors of Early and Sustained Remission Assessed by Various Indices in the French Early Arthritis Espoir Cohort

    Cédric Lukas1, Ihsane Hmamouchi2, Xavier Le Loet3, Bruno Fautrel4 and Bernard Combe5, 1Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France, 2El Ayachi Hospital, Rabat, Morocco, 3Rheumatology Department, CHU de ROUEN, Rouen, France, 4Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, 5Rheumatology, Hopital Lapeyronie, Montpellier, France

    Background/Purpose: Clinical remission is the best achievable state in patients with rheumatoid arthritis (RA). The definition of remission, however, is still under debate. The aim…
  • Abstract Number: 397 • 2012 ACR/ARHP Annual Meeting

    Assessment of Global Disease Activity in Rheumatoid Arthritis Patients Monitored in the Measurement of Efficacy of Treatment in the Era of Rheumatology Database: The patient’s Versus the rheumatologist’s Opinion

    E. Gvozdenovic1, R. Koevoets1, R. Wolterbeek2, Désirée van der Heijde3, T.W.J. Huizinga1, C.F. Allaart1 and Robert B. M. Landewé4, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Biostatistics, Leiden University Medical Center, Leiden, Netherlands, 3Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 4Academic Medical Center/University of Amsterdam & Atrium Medical Center, Amsterdam, Netherlands

    Background/Purpose: Disagreement on disease activity between rheumatoid arthritis (RA) patients and rheumatologists may influence treatment decisions and compliance.  The aim is to compare the physician's…
  • Abstract Number: 398 • 2012 ACR/ARHP Annual Meeting

    Basal Metabolic Rate As an Indicator of Rheumatoid Arthritis Disease Activity and Predictor of Remission

    Heather Jones1, Annette Szumski2 and Andrew S. Koenig3, 1Pfizer Inc., Collegeville, PA, 2Specialty Care, Pfizer Inc., Collegeville, PA, 3Specialty Care Business Unit, Pfizer Inc., Collegeville, PA

    Background/Purpose: The role of body mass index (BMI) in rheumatoid arthritis (RA) disease activity and response to treatment has been difficult to determine.1 As a…
  • Abstract Number: 399 • 2012 ACR/ARHP Annual Meeting

    Can Sustained Remission of Rheumatoid Arthritis Be Predicted? an Analysis From the Japanese National Database of Rheumatic Disease (NinJa)

    Yoichiro Haji1, Mitsumasa Kishimoto1, Ryo Rokutanda1, Sachiko Ohde2, Gautam A. Deshpande3, Yuri Ohara1, Chisun Min1, Yasuhiro Suyama1, Hisanori Shimizu1, Ken-ichi Yamaguchi1, Akira Takeda4, Yukio Matsui1, Masato Okada1 and Shigeto Tohma5, 1Division of Allergy & Rheumatology, St. Luke's International Hospital, Tokyo, Japan, 2Center for Clinical Epidemiology, St.Luke's Life of Science Institute, Tokyo, Japan, 3Center for Clinical Epidemiology, St. Luke's Life Science Instutute, Tokyo, Japan, 4Division of Clinical Immunology & Rheumatology, International University of Health and Welfare Hospital, Nasu-shiobara, Japan, 5Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan

    Background/Purpose: Achievement of clinical remission in rheumatoid arthritis (RA) is now the goal of therapy to reduce joint damage and disability, and maintain or improve…
  • Abstract Number: 400 • 2012 ACR/ARHP Annual Meeting

    High Patient Global Assessment Scores Associate with the Residual Disease Activity Unidentified by a 28-Joint Examination in Rheumatoid Arthritis Patients Approaching Clinical Remission

    Yasushi Inoue1, Eiichi Tanaka2, Ayako Nakajima3, Eisuke Inoue4, Akiko Kobayashi4, Daisuke Hoshi1, Naoki Sugimoto4, Kumi Shidara4, Yohei Seto4, Atsuo Taniguchi4, Shigeki Momohara1 and Hisashi Yamanaka1, 1Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 2Tokyo Women's Medical University, Tokyo, Japan, 3Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, 4Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan

    Background/Purpose: Patient global assessment (PtGA) is a component of the new ACR/EULAR remission criteria for rheumatoid arthritis (RA). It has been reported that >50% of…
  • Abstract Number: 401 • 2012 ACR/ARHP Annual Meeting

    Can We Improve Outcomes in Early Rheumatoid Arthritis by Determining Best Practices?  An Analysis of the Canadian Early Rheumatoid Arthritis Cohort (CATCH)

    Jamie Harris1, Vivian P. Bykerk2, Carol A. Hitchon3, Edward Keystone4, J. Carter Thorne5, Gilles Boire6, Boulos Haraoui7, Glen S. Hazlewood8, Ashley Bonner9, Janet E. Pope10 and CATCH Investigators11, 1Western University, London, ON, Canada, 2Rheumatology, Hospital for Special Surgery, New York, NY, 3University of Manitoba, Winnipeg, MB, Canada, 4University of Toronto, Toronto, ON, Canada, 5Southlake Regional Health Centre, Newmarket, ON, Canada, 6Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, 7Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, 8Medicine, University of Toronto, Toronto, ON, Canada, 9McMaster University, Hamilton, ON, Canada, 10Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, 11Toronto, ON, Canada

    Background/Purpose: The goal of ERA treatment is remission but many patients do not achieve this state due to patient factors and perhaps differences in treating…
  • Abstract Number: 402 • 2012 ACR/ARHP Annual Meeting

    Discordant Inflammatory Markers in Veterans with Rheumatoid Arthritis: Baseline Characteristics and Relationship with Disease Activity

    Rebecca Belsom1, Archana Jain1, Jeffrey R. Curtis2, Shuo Yang3, Ted R. Mikuls4, Lang Chen5 and Angelo L. Gaffo6, 1Rheumatology, University of Alabama, Birmingham, AL, 2Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 3Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 4Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 5Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 6Medicine, Birmingham VA Medical Center and University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Discrepancies between erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) elevations with clinical disease activity frequently occur in rheumatoid arthritis (RA) patients and may…
  • « Previous Page
  • 1
  • …
  • 2574
  • 2575
  • 2576
  • 2577
  • 2578
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology